ARQL - ARQL Stock Jumps to 12-Year High On Encouraging ARQ 531 Data
ARQL stock is having an impressive run on the market today after ArQule, Inc. (NASDAQ:ARQL) announced encouraging data from the Phase 1 trial of ARQ 531, its investigational cancer product.
About Today’s DevelopmentIn this regard, it needs to be pointed out that the product is still being tested and the company is testing as many as 34 patients who are suffering from any of Richter’s Transformation, chronic lymphocytic leukemia (CLL), other B-cell Non-Hodgkin lymphomas, Waldenström macroglobulinemia, or small lymphocytic leukemia (SLL).
The researchers who were responsible for overseeing the Phase 1 study found ...
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.